Ángela León Cáceres

Ángela León Cáceres

Auto-generated profile, based on publicly available information

Ángela León Cáceres

Heidelberg Institute of Global Health, Faculty of Medicine, University of Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2019 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
CPCesar Paz-y-Mino
Cesar Paz-y-Mino
SGSantiago Guerrero
Santiago Guerrero
GJGABRIELA Jaramillo-Koupermann
GABRIELA Jaramillo-Koupermann
ÁCÁngela León Cáceres
Ángela León Cáceres
NSNéstor W. Soria
Néstor W. Soria

26 February 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
PGPatricia Guevara
Patricia Guevara
Nikolaos KyriakidisNikolaos Kyriakidis
Nikolaos Kyriakidis
CBCarlos Barba-Ostria
Carlos Barba-Ostria
ÁCÁngela León Cáceres
Ángela León Cáceres
CPCésar Paz-Y-Miño
César Paz-Y-Miño
Background:There is pressing urgency to identify therapeutic targets and drugs that allow treating COVID-19 patients effectively.Methods:We performedin silicoanalyses of immune system protein interactome network, single-cell RNA sequencing of human tissues, and artificial neural networks to reveal potential therapeutic targets for drug repurposing against COVID-19.Results:We screened 1,584 high-confidence immune system proteins in ACE2 and TMPRSS2 co-expressing cells, finding 25 potential therapeutic targets significantly overexpressed in nasal goblet secretory cells, lung type II pneumocytes, and ileal absorptive enterocytes of patients with several immunopathologies. Then, we performed fully connected deep neural networks to find the best multitask classification model to predict the activity of 10,672 drugs, obtaining several approved drugs, compounds under investigation, and experimental compounds with the highest area under the receiver operating characteristics.Conclusion:After being effectively analyzed in clinical trials, these drugs can be considered for treatment of severe COVID-19 patients. Scripts can be downloaded athttps://github.com/muntisa/immuno-drug-repurposing-COVID-19.

18 March 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
IDIván Dueñas-Espín
Iván Dueñas-Espín
ÁCÁngela León Cáceres
Ángela León Cáceres
AÁAngelica Álava
Angelica Álava
JAJuan Ayala
Juan Ayala
KFKarina Figueroa
Karina Figueroa
JVJohanna Vinces
Johanna Vinces
Objective The current study aims to demonstrate independent associations between social, educational and health practice interventions as determinants of exclusive breastfeeding in an urban Ecuadorian population. Design Prospective survival analyses. Setting Ecuadorian mother–child dyads in urban settings. Participants We followed-up 363 mother–baby dyads who attended healthcare centres in Portoviejo, province of Manabi, for a median time (P25–P75) of 125 days (121–130 days). Main outcome measures We performed a survival analysis, by setting the time-to-abandonment of exclusive breastfeeding measured in days of life, that is, duration of exclusive breastfeeding, periodically assessed by phone, as the primary outcome. Crude and adjusted mixed-effects Cox proportional hazards model were performed to estimate HRs for each explanatory variable. Results The incidence rate of abandonment of breastfeeding was 8.9 per 1000 person-days in the whole sample. Multivariate analysis indicated the three most significant protective determinants of exclusive breastfeeding were (a) sessions of prenatal breastfeeding education with an HR of 0.7 (95% CI: 0.5 to 0.9) per each extra session, (b) self-perception of milk production, with an HR of 0.4 (95% CI: 0.3 to 0.6) per each increase in the perceived quantity of milk production and (c) receiving early skin-to-skin contact with an HR of 0.1 (95% CI: <0.1 to 0.3) compared with those not receiving such contact, immediately after birth. Conclusions Prenatal education on breastfeeding, self-perception of sufficient breast-milk production and early skin-to-skin contact appear to be strong protectors of exclusive breastfeeding among urban Ecuadorian mother–baby dyads.

17 August 2021 in Research Square
Verified
Preprint
Open access
PDF file
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
SGSantiago Guerrero
Santiago Guerrero
EOEsteban Ortiz-Prado
Esteban Ortiz-Prado
VYVeronica Yumiceba
Veronica Yumiceba
AVAntonella Vera-Gupi
Antonella Vera-Gupi
Nikolaos KyriakidisNikolaos Kyriakidis
Nikolaos Kyriakidis
There is pressing urgency to identify drugs that allow treating COVID-19 patients effectively. Respiratory failure is the leading cause of death in patients with severe COVID-19, and the host inflammatory response at the lungs remains poorly understood. Therefore, we retrieved data from postmortem lungs from COVID-19 patients and performed in-depth in silico analyses of single-nucleus RNA sequencing data, inflammatory protein interactome network, functional enrichment, and shortest pathways to cancer hallmark phenotypes to reveal potential therapeutic targets and drugs in advanced-stage COVID-19 clinical trials. Herein, we analyzed transcriptomics data of 719 inflammatory response genes across 19 cell types (116,313 nuclei) from lung autopsies. The functional enrichment analysis of the 233 significantly expressed genes showed that the most relevant biological annotations were: inflammatory response, innate immune response, cytokine production, interferon production, macrophage activation, thymic stromal lymphopoietin, blood coagulation, IL-1 and megakaryocytes in obesity, NLRP3 inflammasome complex, and the TLR, JAK-STAT, NF-κB, TNF, oncostatin M, AGE-RAGE signaling pathways. Subsequently, we identified 34 essential inflammatory proteins with both high-confidence protein interactions and shortest pathways to inflammation, cell death, glycolysis, and angiogenesis. Lastly, we propose five small molecules involved in advanced-stage COVID-19 clinical trials: baricitinib, pacritinib, and ruxolitinib are tyrosine-protein kinase JAK2 inhibitors, losmapimod is a MAP kinase p38 alpha inhibitor, and eritoran is a TLR4/MD-2 antagonist. After being thoroughly analyzed in COVID-19 clinical trials, these drugs can be considered for treating severe COVID-19 patients.

3 June 2020 in ChemRxiv
Verified
Preprint
Open access
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
PGPatricia Guevara
Patricia Guevara
Nikolaos KyriakidisNikolaos Kyriakidis
Nikolaos Kyriakidis
Carlos Barba-OstriaCarlos Barba-Ostria
Carlos Barba-Ostria
ÁCÁngela León Cáceres
Ángela León Cáceres
CPCesar Paz-Y-Miño
Cesar Paz-Y-Miño
There is pressing urgency to better understand the immunological underpinnings of the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2) in order to identify potential therapeutic targets and drugs that allow treating patients effectively. To fill in this gap, we performed in silico analyses of immune system protein interactome network, single-cell RNA sequencing of human tissues, and artificial neural networks to reveal potential therapeutic targets for drug repurposing against COVID-19. As results, the high-confidence protein interactome network was conformed by 1,588 nodes between immune system proteins and human proteins physically associated with SARS-CoV-2. Subsequently, we screened all these nodes in ACE2 and TMPRSS2 co-expressing cells according to the Alexandria Project, finding 75 potential therapeutic targets significantly overexpressed (Z score > 2) in nasal goblet secretory cells, lung type II pneumocytes, and ileal absorptive enterocytes of patients with several immunopathologies. Then, we performed fully connected deep neural networks to find the best multitask classification model to predict the activity of 10,672 drugs for 25 of the 75 aforementioned proteins. On one hand, we obtained 45 approved drugs, 16 compounds under investigation, and 35 experimental compounds with the highest area under the receiver operating characteristic (AUROCs) for 15 immune system proteins. On the other hand, we obtained 4 approved drugs, 9 compounds under investigation, and 16 experimental compounds with the highest multi-target affinities for 9 immune system proteins. In conclusion, computational structure-based drug discovery focused on immune system proteins is imperative to select potential drugs that, after being effectively analyzed in cell lines and clinical trials, these can be considered for treatment of complex symptoms of COVID-19 patients, and for co-therapies with drugs directly targeting SARS-CoV-2.